Morgan Stanley Provides Color on Bristol Myers Squibb

Morgan Stanley Provided Color on Bristol Myers Squibb BMY. In a research report published today, Morgan Stanley states, “We expect 2013 EPS guidance to remain unchanged at minimum $1.95. In conjunction with long-term strategic planning in June, we expect Bristol to update its 2013 comments when it reports results (likely July 28th). Given apixaban's stronger-than-expected profile (superiority to warfarin on both efficacy and bleeding), we think BMY/PFE will want to invest incrementally more in the late 2012 launch in order to fully capitalize on the bigger opportunity… Hence, we expect unchanged 2013 EPS guidance of minimum $1.95.” At the moment, Morgan Stanley has an Overweight rating placed on the company's stock. On Wednesday, Bristol Myers closed the day at $28.54. Its shares added 1.16% to their value in today's pre-market trading to trade around $28.87.